ZJ43 是一种 NAAG 肽酶抑制剂和 GCP II/III 抑制剂,对人 GCP II 的 IC50 为 2.4 nM、Ki 为 0.8 nM,可通过阻断 N-乙酰天冬氨酰谷氨酸水解、提高细胞外 N-乙酰天冬氨酰谷氨酸水平并激活 II 型 mGluR,用于精神分裂症、炎性疼痛、神经性疼痛和创伤性脑损伤的相关研究。
产品编号: MS-E89946 纯度: 99.6% CAS No.: 723331-20-2 分子式: C12H20N2O7 分子量: 304.30
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
询价
10mg
询价
询价

产品描述

ZJ43 是一种 NAAG 肽酶抑制剂和 GCP II/III 抑制剂,对人 GCP II 的 IC50 为 2.4 nM、Ki 为 0.8 nM,可通过阻断 N-乙酰天冬氨酰谷氨酸水解、提高细胞外 N-乙酰天冬氨酰谷氨酸水平并激活 II 型 mGluR,用于精神分裂症、炎性疼痛、神经性疼痛和创伤性脑损伤的相关研究。

生物实验数据

生物活性 ZJ43 is a NAAG peptidase inhibitor and GCP II/III inhibitor with an IC50 of 2.4 nM and a Ki of 0.8 nM against human GCP II, and it blocks N-acetylaspartylglutamate hydrolysis, elevates extracellular N-acetylaspartylglutamate levels, and activates group II mGluR, making it useful for research related to schizophrenia, inflammatory pain, neuropathic pain, and traumatic brain injury.
IC50 & Target

group II mGlu receptors

 

体外研究
(In Vitro)

ZJ43 (2 小时) 可强效抑制克隆的人 GCP II,其 Ki 值为 0.8 nM。
ZJ43 以 23 nM 的 Ki 值抑制克隆的小鼠 GCP III。
ZJ43 (2 小时) 可抑制克隆大鼠 GCPII,其 Ki 值为 3 nM。

体内研究
(In Vivo)

ZJ43 (150 mg/kg;腹腔注射;单次给药) 可通过一种依赖于 II 型 mGluR 的机制,显著减轻雄性 Sprague-Dawley 大鼠中由 PCP 诱导的多种类精神分裂症行为症状。
ZJ43 (10-100 mg/kg;静脉注射;单次给药) 可在大鼠福尔马林炎性疼痛模型中产生剂量依赖性镇痛作用。
ZJ43 (10-100 mg/kg;静脉注射;单次给药) 可在大鼠坐骨神经部分结扎神经病理性疼痛模型中产生剂量依赖性的抗异常痛觉作用。
ZJ43 (100 mg/kg;静脉注射;单次给药) 不改变健康大鼠对有害机械或热刺激的急性痛觉反应。
ZJ43 (50-150 mg/kg;腹腔注射;每 8 小时 1 次;共 3 次) 可显著减轻大鼠侧方液压冲击脑创伤模型中同侧神经元的变性。

Animal Model: Sprague-Dawley (male, 280-330 g, PCP-induced schizophrenia-like symptoms)
Dosage: 150 mg/kg
Administration: i.p.; single dose
Result: Significantly reduced PCP-induced motor activity, with a statistically significant difference in total distance traveled between 80-180 min compared to PCP-only treated rats (p = 0.021).
Significantly increased the frequency of rats being "still" (p = 0.015).
Significantly reduced PCP-induced stereotypic falling (p = 0.02), circling movements (p ≤ 0.001), total head movements (p = 0.005), and head bobbing (p = 0.004) compared to PCP-only treated rats.
Produced a non-statistically significant trend toward reduced PCP-induced mouth movements, tremors, and sideways head movements.
Failed to reduce PCP-induced sniffing and showed a non-significant tendency to increase this behavior (p = 0.17).
Animal Model: Rats (Formalin-induced inflammatory pain model)
Dosage: 10 mg/kg; 100 mg/kg
Administration: i.v.; single dose
Result: Decreased cumulative formalin-evoked flinches in both phase 1 (0-6 minutes) and phase 2 (10-60 minutes) in a dose-dependent manner (phase 1 P < 0.005, phase 2 P < 0.001).
Reduced flinching to ~50% of vehicle response in phase 1 and ~30% of vehicle response in phase 2 at 100 mg/kg.
Animal Model: Rats (partial sciatic nerve ligation neuropathic pain model)
Dosage: 10 mg/kg; 100 mg/kg
Administration: i.v.; single dose
Result: Significantly increased the maximum 50% probability mechanical withdrawal threshold in a dose-dependent manner (P < 0.001).
Elevated the threshold to ~13 g at 100 mg/kg (compared to ~2 g in saline-treated rats).
Animal Model: Rats
Dosage: 100 mg/kg
Administration: i.v.; single dose
Result: Had no significant effect on the number of paw withdrawal responses to noxious mechanical stimulation, with maximum responses (18.8) and minimum responses (15.6) not differing significantly from saline-treated rats (P > 0.3).
Had no significant effect on hotplate response latency, with % maximum possible effect (-9.9) not differing significantly from saline-treated rats (P > 0.8).
Animal Model: Sprague-Dawley (male, 340 g, lateral fluid percussion TBI moel)
Dosage: 50 mg/kg; 100 mg/kg; 150 mg/kg
Administration: i.p.; every 8 h; 3 total doses
Result: Significantly reduced the number of ipsilateral degenerating neurons in the hippocampal CA2/3 regions compared to vehicle (p < 0.01).
Reduced ipsilateral astrocyte loss to 14.0% versus 30.6% in the vehicle group at 50 mg/kg dose (p = 0.05; p = 0.007).
性状 固体
颜色 Colorless to off-white

化学信息

分子量 304.30
分子式 C12H20N2O7
CAS No. 723331-20-2

储存&溶解度

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础